Navigation Links
Regulus Reports Third Quarter 2012 Financial Results and Recent Highlights
Date:11/19/2012

LA JOLLA, Calif., Nov. 19, 2012 /PRNewswire/ -- Regulus Therapeutics Inc. (NASDAQ: RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today reported financial results for the quarter ended September 30, 2012 and provided a summary of recent corporate highlights.

"The third quarter and subsequent period were the most successful to date for Regulus as measured by the achievement of significant financial and strategic goals," said Kleanthis G. Xanthopoulos, Ph.D., President and CEO of Regulus. "Regulus is now focused on the execution of our research and development plans that include selection of clinical candidates in all of our microRNA therapeutic programs, which we believe will enable us to file at least two INDs by 2014."

"We expect that the capital raised in the last several months will provide sufficient funding for operations through at least the end of 2015," said Garry E. Menzel, Ph.D., Chief Operating Officer and Executive Vice President of Finance. "We believe our disciplined financial strategy will enable us to advance multiple programs toward the clinic without the need for additional equity financing."

Third Quarter 2012 and Recent Corporate Highlights

  • Completed Initial Public Offering ("IPO"). In October 2012, Regulus completed its IPO, raising $50.9 million in gross proceeds, inclusive of the over-allotment option exercised by the underwriters and insider participation by Isis Pharmaceuticals, Inc., one of its founding companies, and two of its strategic partners, Sanofi SA ("Sanofi") and GlaxoSmithKline plc ("GSK").  Regulus' common stock began trading on the NASDAQ Global Market on October 4, 2012 under the symbol "RGLS."
  • Established Significant S
    '/>"/>

  • SOURCE Regulus Therapeutics Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7

    Related medicine technology :

    1. Regulus Announces Timing for Third Quarter 2012 Financial Results Webcast and Conference Call
    2. Regulus Appoints Douglas E. Williams, Ph.D. to its Board of Directors
    3. Regulus Announces $80.9 Million in Total Gross Proceeds from IPO and Other Recent Financial Transactions
    4. Regulus Presents New Preclinical Data on miR-21 at Kidney Week 2012
    5. Biogen Idec and Regulus Therapeutics Form Collaboration to Explore microRNA Biomarkers for Disease Monitoring and Response to Therapy
    6. Regulus Therapeutics Forms Strategic Alliance for Discovery, Development and Commercialization of microRNA Therapeutics with AstraZeneca
    7. Grupo Casa Saba Reports - Grupo Casa Saba Announces its Intention to Delist From the New York Stock Exchange
    8. Solos Endoscopy Reports Book Value of $2,393,522 for Period Ended September 30, 2012
    9. ULURU Inc. Reports Third Quarter 2012 Financial Results
    10. Simcere Pharmaceutical Group Reports Preliminary Unaudited Third Quarter 2012 Results
    11. China Pharma Holdings, Inc. Reports Third Quarter 2012 Financial Results
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/29/2014)... 2014 Pfenex Inc. (NYSE MKT: PFNX) today announced ... of 8,333,333 shares of its common  stock at a price ... common stock was offered by Pfenex. In addition, Pfenex has ... 1,250,000 additional shares of common stock at the initial public ... the NYSE MKT under the symbol "PFNX." ...
    (Date:7/29/2014)... , July 29, 2014  Landauer, Inc. (NYSE: ... and environmental radiation measurement and monitoring, outsourced medical physics ... financial results for the fiscal third quarter 2014 after ... The Company will host a conference call ... a.m. Central Time (10 a.m. Eastern Time). Investors may ...
    (Date:7/29/2014)... 29, 2014  Synthetic Biologics, Inc. (NYSE MKT: SYN), ... targeting specific pathogens that cause serious infections and diseases, ... activity in the Company,s stock, the NYSE MKT (the ... usual practice. The Company stated that its policy is ... About Synthetic Biologics, Inc. Synthetic Biologics, Inc. ...
    Breaking Medicine Technology:Pfenex Announces Closing of Initial Public Offering 2Landauer, Inc. Sets Date and Time for Announcement of Fiscal Third Quarter 2014 Results 2Synthetic Biologics, Inc. States that Its Policy is Not to Comment on Unusual Market Activity 2
    ... , MINNETONKA, Minn., Dec. 1 ... company specializing in clinical study management systems, today ... technology solution, has been certified by the Clinical ... the Operational Data Model (ODM) standard. This ...
    ... , CAMBRIDGE, Mass. and TOKYO, Dec. 1 Galenea ... further extension of their research and development collaboration through ... to seven years and brings the total committed funding ... working together since January 2005 with the goal of ...
    Cached Medicine Technology:MedNet Solutions' ENLIGHTEN Receives CDISC ODM Certification 2Galenea and Otsuka Announce Second Extension to Schizophrenia Research Collaboration 2Galenea and Otsuka Announce Second Extension to Schizophrenia Research Collaboration 3
    (Date:7/29/2014)... Alan Mozes HealthDay Reporter ... adult autism patients with just a single dose of the ... and emotions, Japanese researchers report. Known as the "love ... emotional bonding between lovers, and between mothers and their children. ... a key area of the brain that has long been ...
    (Date:7/29/2014)... 29, 2014 Summer is here, and that means ... a hike, swimming in a pool or laying out on the ... and ticks. The Puppy Store is here to help pet owners ... , It’s almost impossible to completely keep fleas and ticks at ... the chances of their pets coming into contact with fleas and ...
    (Date:7/29/2014)... Bret Busacker , a partner ... has been appointed to the Board of Directors for ... is an experienced business attorney with a focus on ... on a wide spectrum of topics regarding equity and ... governance concerns. His clients include public and private businesses, ...
    (Date:7/29/2014)... The report, “Heat Transfer Fluids Market by ... Fluids, & Others), by Application (Oil & Gas, Chemical, ... Trends & Forecasts to 2019” defines and segments the ... forecast of the global consumption in terms of volume ... figures spread through 199 page sand in-depth TOC on"Heat ...
    (Date:7/29/2014)... (HealthDay News) -- Quitting smoking is harder for people with ... can make it more difficult to ride out the anxiety, ... quit cold turkey, scientists found. But extra exercise -- even ... said. "The review should be seen as a call ... in the department of exercise science at Concordia University in ...
    Breaking Medicine News(10 mins):Health News:'Love Hormone' Oxytocin May Help Some With Autism 2Health News:'Love Hormone' Oxytocin May Help Some With Autism 3Health News:Protect Dogs From Fleas and Ticks During the Summer 2Health News:Holland & Hart Partner Brett Busacker Appointed to Board of Directors for American Red Cross of Greater Idaho 2Health News:Heat Transfer Fluids Market Expected to Grow 641,218.19 Tons by 2019 – New Report by MarketsandMarkets 2Health News:Heat Transfer Fluids Market Expected to Grow 641,218.19 Tons by 2019 – New Report by MarketsandMarkets 3Health News:Heat Transfer Fluids Market Expected to Grow 641,218.19 Tons by 2019 – New Report by MarketsandMarkets 4Health News: Extra Exercise Could Help Depressed Smokers Quit: Study 2
    ... grains and cereals and of magnesium may each be associated ... a report and meta-analysis in the issue of Archives ... of people diagnosed with diabetes worldwide may increase from 171 ... background information in the article. The associated illness, death and ...
    ... Those men who are facing the surgical removal of ... day will come when they need not worry ... a team of expert urologic surgeons at NewYork-Presbyterian Hospital/Weill ... of reconstructing key anatomical structures that ensure continence. ...
    ... Maine in Portland have revealed that Depleted Uranium (DU) weapons ... has been denying the possibility. ,Previous research at ... that people exposed to DU dust were at little extra ... inadequately radioactive metal that is used in armour-piercing shells and ...
    ... shown that subtle signs may enable early prediction of Huntingtons ... and some aspects of personality. ,Dr. Jane ... Lucille A. Carver College of Medicine in Iowa City studied ... ,Each of the participants had at least one parent who ...
    ... bad tidings for those heavy-handed on multivitamins. The research conducted ... who take more than seven multivitamin tablets a week, can ... type of prostate cancer. ,The researchers who ... Cancer Institute, followed 295,344 men who reported ...
    ... day could help improve fitness and health of women who ... ,Conducting tests on overweight and obese women, many of whom ... Rouge found that even ten minutes of exercise a day ... their overall risk of early death. ,The study ...
    Cached Medicine News:Health News:Risk of Diabetes is Reduced by Intake of Grain Fiber and Magnesium 2Health News:Innovative Procedure Helps Men Minimize Incontinence After Prostatectomy 2Health News:Innovative Procedure Helps Men Minimize Incontinence After Prostatectomy 3Health News:Early Prediction of Huntingtons Disease is Possible by Subtle Signs 2Health News:Being Overzealous With Multivitamins May Lead To Prostate Cancer 2
    ... Steri-Cath™ Closed Ventilation Suction Systems Reduce ... Constant Patient Ventilation, ,Cost-effective and ... Ventilation Suction Systems reduces the risk ... contact with the catheter, Steri-Cath™ maintains ...
    ... Catheters are available in two ... DeLee tip with staggered eyes, ... Two types of catheter valve ... easy fingertip control with virtually ...
    ... Catheters are available in two ... DeLee tip with staggered eyes, ... Two types of catheter valve ... easy fingertip control with virtually ...
    ... Our Tri-Flo® suction catheter design ... to your patients while still providing ... pediatric catheters (5/6, 8 or 10 ... facilitate proper catheter placement. Our complete ...
    Medicine Products: